Natural Compound

Mucuna Pruriens

Mucuna pruriens

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

200–600 mg per day (standardized to 15–20% L-DOPA)

watchEffect Window

Acute (30–60 minutes) for motor symptoms and mood.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Mucuna pruriens is a legume whose seeds contain L-DOPA, a dopamine precursor. It is used for mood and motivation goals and for movement symptom support in dopaminergic contexts.

Clinical studies show mucuna can improve Parkinsonian motor symptoms due to L-DOPA content, though dosing variability complicates reliability. Trials also suggest improvements in male fertility markers and libido, potentially through dopamine and antioxidant effects. Minority evidence includes stress and mood benefits. Benefits depend on verified L-DOPA content, and side effects can mirror dopaminergic stimulation.

Natural source of L-DOPA (3.6–4.2%), the direct precursor to dopamine that crosses the blood-brain barrier. Also contains minor serotonin and 5-HTP with antioxidant properties.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Reduce motor symptoms of Parkinson's disease
  • Natural source of L-DOPA

Secondary Outcomes

  • Mood improvement
  • Modest testosterone increase in stressed/infertile men
  • Cortisol reduction

Safety

Contraindications and Interactions

Contraindications

  • Concurrent levodopa/carbidopa therapy without clinician oversight
  • Psychosis/schizophrenia
  • Significant cardiovascular disease or arrhythmia
  • Pregnancy
  • Lactation

Side effects

  • Nausea or GI upset
  • Headache
  • Dizziness or drowsiness
  • Itching with raw pod contact
  • Dyskinesia at high doses

Interactions

  • Levodopa/carbidopa (additive levodopa exposure, dyskinesia and blood-pressure variability risk)
  • Dopamine agonists (additive dopaminergic adverse effects)
  • Monoamine oxidase inhibitors (hypertensive reaction risk)
  • Antipsychotics (opposing pharmacology, efficacy reduction risk)
  • CYP3A4 substrate drugs or supplements (theoretical exposure changes)
  • Blood-glucose-lowering drugs or supplements (possible additive glucose lowering)
  • Vitamin B6 at high doses (theoretical change in peripheral levodopa metabolism)

Avoid if

  • Taking prescription levodopa without medical oversight
  • Psychosis/schizophrenia
  • Cardiovascular arrhythmias or unstable cardiovascular disease
  • Pregnancy or lactation

Evidence

Study-level References

mucuna-pruriens-SRC-001RCT (Double-blind crossover)
Sourceopen_in_new

Katzenschlager R, et al. "Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study." J Neurol Neurosurg Psychiatry. 2004.

Population: Patients with Parkinson's disease

Key findings: Compared to standard L-DOPA/carbidopa, Mucuna pruriens showed a significantly faster onset of effect, a longer duration of clinical response, and fewer dyskinesias.

Paper content

Compared to standard L-DOPA/carbidopa, Mucuna pruriens showed a significantly faster onset of effect, a longer duration of clinical response, and fewer dyskinesias.

mucuna-pruriens-SRC-002RCT
Sourceopen_in_new

Cilia R, et al. "Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study." Neurology. 2017.

Population: Advanced Parkinson's disease patients

Key findings: Single-dose Mucuna intake met all noninferiority efficacy and safety outcomes compared to levodopa/benserazide, with a more favorable tolerability profile.

Paper content

Single-dose Mucuna intake met all noninferiority efficacy and safety outcomes compared to levodopa/benserazide, with a more favorable tolerability profile.

mucuna-pruriens-SRC-003Multicenter, randomized, open-label, phase 2 trial.
Sourceopen_in_new

Cilia R, Cham M, Obese V, et al. Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: a 12-month, multicenter, randomized, controlled trial. J Parkinsons Dis. 2026;16(1):99-109. doi:10.1177/1877718X251383721. PMID:41269916.

Population: Untreated Parkinson's disease patients in sub-Saharan Africa (Ghana).

Dose protocol: Roasted Mucuna pruriens powder (dose adjusted for body weight and disease stage) vs standard levodopa/DDCI for 12 months

Key findings: Comparable effectiveness for motor symptoms, non-motor symptoms, and quality of life over 12 months. Adverse events numerically higher with mucuna (56% vs 37.5%) but not significant. Most mild.

Notes: Longest controlled mucuna trial to date. Open-label design and small sample (n=32) are limitations.

Paper content

This 12-month multicenter phase 2 RCT in Ghana compared roasted Mucuna pruriens powder to standard levodopa/DDCI in 32 treatment-naive Parkinson's disease patients. Mucuna showed comparable effectiveness for motor symptoms, non-motor symptoms, and quality of life over the full 12-month period. Adverse events occurred more frequently with mucuna (56% vs 37.5%) but the difference was not statistically significant, and most were mild. Only 12.5% discontinued due to adverse effects. This is the longest controlled mucuna trial published to date, and it meaningfully extends the evidence beyond prior acute and short-term studies. The open-label design and small sample size are notable limitations, but the 12-month duration and multicenter design add confidence to the tolerability and durability findings.

mucuna-pruriens-SRC-004Randomized, single-blind, crossover trial.
Sourceopen_in_new

Boonmongkol T, Phokaewvarangkul O, Vimolmangkang S, et al. Comparative efficacy of Mucuna pruriens and conventional levodopa in Parkinson's disease: a randomized controlled trial on pharmacokinetics and clinical perspectives from Asia. J Neural Transm (Vienna). 2025;132(11):1673-1683. doi:10.1007/s00702-025-02914-2. PMID:40137945.

Population: Adults with Parkinson's disease (Asia-based cohort).

Dose protocol: Single 30 g Mucuna pruriens powder vs 200/50 mg levodopa/benserazide in crossover design with 2-week washout

Key findings: Higher levodopa exposure (AUC ratio 155.67%) and significantly longer dyskinesia-free ON time (232.2 vs 161.8 min, P=0.01) with mucuna. Mild nausea and dizziness more common.

Notes: Adds pharmacokinetic data from Asia. Small sample (n=11) but strong crossover design.

Paper content

This single-blind crossover RCT in 11 Parkinson's disease patients compared a single 30 g dose of Mucuna pruriens powder to standard levodopa/benserazide. Mucuna produced significantly higher levodopa exposure (AUC ratio 155.67%) and a significantly longer ON state without dyskinesia (232.2 vs 161.8 minutes, P=0.01). Absorption and elimination kinetics were comparable. Mild, transient nausea and dizziness were more common with mucuna. This trial from Asia adds geographic and pharmacokinetic diversity to the mucuna evidence base. The higher drug exposure and longer dyskinesia-free ON time are consistent with prior work suggesting the plant matrix may offer pharmacokinetic advantages. The small sample (n=11) limits generalizability but the crossover design strengthens within-subject comparisons.

Guides

Setup

Help